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Abstract (224 words) 
Recent studies of muscle-invasive bladder cancer show that FGFR3 mutations are generally 
found in a luminal papillary tumour subtype that is characterised by better survival than other 
molecular subtypes. To better understand the role of FGFR3 in invasive bladder cancer, we 
examined the process of tumour development induced by the tobacco carcinogen OH-BBN in 
genetically engineered models that express mutationally activated FGFR3 S249C or FGFR3 
K644E in the urothelium. Both occurrence and progression of OH-BBN-driven tumours were 
increased in the presence of an S249C mutation compared to Wildtype control mice. 
Interestingly, at an early tumour initiation stage, the acute inflammatory response in OH-BBN-
treated bladders was suppressed in the presence of an S249C mutation. However, at later stages 
of tumour progression, increased inflammation was observed in S249C tumours, long after the 
carcinogen administration had ceased. Early-phase neutrophil depletion using an anti-Ly6G 
monoclonal antibody resulted in an increased neutrophil-to-lymphocyte ratio at later stages of 
pathogenesis, indicative of enhanced tumour pathogenesis, which supports the hypothesis that 
suppression of acute inflammation could play a causative role. Statistical analyses of correlation 
showed that while initial bladder phenotypes in morphology and inflammation were FGFR3-
dependent, increased levels of inflammation were associated with tumour progression at the 
later stage. This study provides a novel insight into the tumour-promoting effect of FGFR3 
mutations via regulation of inflammation at the pre-tumour stage in the bladder.  
 
Keywords: transitional cell carcinoma, transgenic mouse model, fibroblast growth factors, 
cancer immunology, neutrophils, inflammation, comparative pathology
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Introduction  
 
Bladder cancer is the 10
th
 most common cancer type, particularly in aging men (Cancer 
Research UK, (http://www.cancerresearchuk.org/about-cancer/bladder-cancer/about, [accessed 
on 16/7/18]).  The majority of bladder cancers are urothelial cell carcinoma (90%), followed by 
squamous cell carcinoma. Smoking is a major risk factor for bladder cancer. The majority of 
urothelial cell carcinoma at diagnosis is non-muscle invasive (NMIBC) (70%), the remainder 
showing muscle invasion. Muscle invasive bladder cancer (MIBC) without metastasis is 
managed by neoadjuvant chemotherapy followed by radical cystectomy [1]. However the 
recurrence rate is high, leading to local (10-15%) and distant (50%) metastasis.  
 
Identifying effective therapies has been a challenge for bladder cancer clinically and pre-
clinically, owing to a lack of full understanding of disease mechanisms [2]. However recent 
molecular analyses of large numbers of MIBC have defined several molecular subtypes and 
identified a range of potential therapeutic targets [3-7]. Abnormal immune regulation promotes 
tumour progression in many cancer types and could be an effective target for therapy [8]. Indeed, 
Bacillus Calmette-Guérin (BCG) immunotherapy is an effective adjuvant therapy for high-risk 
NMIBC that reduces disease recurrence and progression, and is offered as standard therapy [1]. 
More recently, clinical trials of inhibitors of immune checkpoint proteins, such as Programmed 
cell death protein 1 (PD-1) and PD ligand 1 (PD-L1), have shown success in advanced bladder 
cancer in terms of response rate and durability [2,9]. Nevertheless, reliable predictive 
biomarkers are lacking, and the role of acute and chronic inflammation and tumour immunity is 
still poorly understood in bladder cancer. 
 
Fibroblast Growth Factor Receptor 3 (FGFR3) mutation and overexpression are common in 
bladder cancer [10-12]. According to the recent molecular classification of MIBC, tumours with 
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FGFR3 mutation and overexpression are associated with urothelial-like or luminal papillary 
tumour subgroups that are characterised by better survival than other molecular subtypes [7,13]. 
An activating point mutation in FGFR3
 C746C>G
, encoding the FGFR3 S249C oncoprotein, 
accounts for 48-71% of all FGFR3 mutations in non-invasive urothelial cell carcinoma [14,15]. 
S249C affects the linker region between the extracellular immunoglobulin-like domains Ig2 and 
Ig3, which is important for the binding of FGF ligands. S249C triggers kinase activation through 
receptor dimerization as a result of disulphide bond formation in a completely ligand-
independent manner [16]. In contrast, a lysine to glutamic acid substitution, K650E, in the 
kinase domain of FGFR3, found in a small number of bladder tumours (~1% of all mutations), 
exaggerates ligand-dependent kinase activation. Overexpression of wildtype FGFR3 receptor is 
found in 42% of muscle-invasive tumours [14]. An oncogenic fusion event of FGFR3 with the 
transforming acidic coiled-coil containing protein 3 (FGFR3-TACC3), leading to constitutive 
activation of FGFR3, is also found in bladder cancer [7,17,18].  
 
FGFR3 is one of four tyrosine kinase receptors for FGFs [15,19]. In vitro studies have provided 
evidence that mutational activation of FGFR3 through S249C or K644E can modestly increase 
cell proliferation and reduce apoptosis, and that various FGFR inhibitors are effective in its 
functional suppression [19]. Current clinical trials are based on proof-of-principle studies in cell 
lines and xenograft models [20-24]. Phase II clinical trials of dovitinib, a multi-targeted RTK 
inhibitor that prevents phosphorylation of FGFR3, showed limited activity in advanced bladder 
cancer [25] and in BCG-unresponsive bladder cancer with mutations or overexpression of 
FGFR3 [26]. In contrast, a phase I trial of BGJ398 showed anti-tumour activity in FGFR3-
mutated advanced bladder cancer after failure of platinum-based chemotherapy [27]. A phase I 
trial using an intermittent dosing schedule of the pan-FGFR3 inhibitor JNJ-42756493 on 
patients with advanced bladder cancer with confirmed FGFR alterations [28] and a case report 
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for phase I AZD4547, a selective FGFR inhibitor targeting FGFR1/2/3 [29] also showed 
promising results.  
 
A better understanding of the role of FGFR3 mutations in tumour pathogenesis and progression 
will help in interpreting trial outcomes and allow further stratifications. The use of in vivo 
models closely reflecting the disease conditions would increase robustness and confidence in 
translation of pre-clinical findings to trials. Previously, we showed in a mouse model of 
spontaneous tumour formation that murine Fgfr3 K644E (equivalent to human K650E) in 
combination with Pten loss was able to induce morphological changes in the urothelium with 
cellular characteristics indicative of abnormal differentiation [30,31]. One of the most well-
studied bladder carcinogens in mice is N-butyl-N-(4-hydroxybutyl)-nitrosamine (OH-BBN), 
derived from tobacco smoke [32]. OH-BBN induced tumours are of a highly invasive nature and 
often show a mixed histology with characteristics of both urothelial cell carcinoma and 
squamous cell differentiation. Similarities in histopathology and pathogenesis between the OH-
BBN model and muscle-invasive bladder tumours in humans have been well established [33,34]. 
 
In this study, we have generated a novel transgenic mouse line that expresses FGFR3 S249C in 
the urothelium and compared the effects of OH-BBN to a Wildtype control, as well as to the 
previously reported Fgfr3 K644E model [30,31]. Furthermore, by neutrophil depletion, we have 
tested the hypothesis that impairment of acute inflammatory response at an early tumour 
initiation stage could promote tumour development.  
 
Materials and methods 
 
Mice: Generation of Tg(UroII-hFGFR3IIIbS249C) ("FGFR3
S249C
") is described in 
supplementary material, Supplementary materials and methods. UroIICre Fgfr3
+/K644E
 were 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
generated as previously described [31]. The Wildtype mice were C57Bl/6 (Charles River, 
Tranent, UK). Genetic background was C57Bl/6 in all cohorts. 
 
Carcinogen treatment: Mice were administered 0.05% v/v OH-BBN (#B0938, TCI UK, 
Birkenhead, UK) in drinking water three times a week for 10 weeks, starting from 8-16 weeks 
of age, followed by 10 weeks of water. All experiments were performed according to an 
approved Project Licence under Home Office Animal (Scientific Procedures) Act 1986. 
 
Neutrophil depletion: Wildtype mice were injected (i.p) with 500 μg of either 1A8 monoclonal 
antibody (anti-mLy-6G, Bioxcell, West Lebanon, NH, USA) or 2A3 isotype control (Rat IgG2a, 
Bioxcell) 3 times per week for 10 weeks, with concurrent OH-BBN administration in drinking 
water. Blood was collected in EDTA-containing tubes by cardiac puncture following euthanasia. 
White blood cell populations were analysed using ProCyte Dx Hematology Analyzer (IDEXX, 
Westbrook, ME, USA). 
 
Histology and Immunohistochemistry (IHC): Methods and antibody details are provided in 
supplementary material, Supplementary materials and methods. 
 
Scoring criteria: The number of mice showing the specific criterion was recorded, as assessed 
on one cross section per bladder. On the rare occasion that multiple lesions with different 
scoring criteria were present within one section, the more severe criterion was assigned. 
 
Tumour phenotype; Stage of pathogenesis (minimal changes, urothelial hyperplasia or atypia, 
dysplastic urothelium or carcinoma in situ (CIS), tumour), "big" tumour, tumour size >50% of 
the bladder, "small" tumour, tumour size is <50% of the bladder; invasiveness (normal basement 
membrane, ambiguous basement membrane, breakage of basement membrane at multiple sites, 
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stromal invasion, muscle invasion, severe muscle invasion); lobulation of the basement 
membrane (none, mild or present locally, severe or multiple sites); squamous transformation 
(none, mild or small area, advanced, fully transformed and often keratinised). Urothelial 
phenotype at 2 weeks; atypia/dysplasia (minimal changes, atypia, dysplasia). Inflammatory 
phenotype and neutrophils: thickness of the stroma (normal, thickened, very thickened); 
angiogenesis in the inner stroma and in the outer stroma (normal, mild increase, notable 
increase). Neutrophil infiltrations at 2 and 12 weeks were scored in the urothelium, or stroma 
and muscle, using the criteria (<5, 6-20, 21-50, >50), where section size of the bladders were 
comparable among samples. Inflammatory phenotype at 20 weeks was scored using the criteria 
modified from Klintrup’s method [35] (absent, presence of immune cells sparsely distributed, 
increase of immune cells clustering, very prominent inflammatory reaction).  
 
Analysis of gene expression in TCGA cohorts and statistics: Details are provided in 
supplementary material, Supplementary materials and methods. The specific statistical method 
used is indicated in Figure legends. P< 0.05 was considered as statistically significant. 
 
Results  
 
Carcinogen-dependent tumorigenesis was increased in transgenic mice expressing 
mutationally-activated FGFR3 S249C.  
 
In order to determine whether an S249C mutation in FGFR3 drives tumour pathogenesis in the 
bladder, we generated a transgenic mouse line that expresses the human FGFR3 IIIb isoform 
with an S249C mutation under control of the mouse uroplakin II promoter, Tg(UroII-
hFGFR3IIIbS249C) ("FGFR3
S249C
"). The histological appearance of the FGFR3
S249C
 urothelia 
(n=17) appeared normal at 12 months of age (Figure 1, spontaneous tumour formation, Table 1, 
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supplementary material, Figure S1). This was similar to observations in mice expressing the 
isogenic Fgfr3b-S249C transgene [36], as well as to heterozygous Fgfr3 K644E (UroIICre 
Fgfr3
+/K644E
, "Fgfr3
K644E
"), which we reported earlier
 
[30,31], supporting that an FGFR3 
mutation by itself is not able to induce urothelial pathogenesis. Furthermore, bladders of double 
mutant mice with both FGFR3
S249C 
and Pten loss, "FGFR3
S249C 
Pten" did not show any 
noticeable histological abnormalities at 12 months of age (n=12) (Table 1, supplementary 
material, Figure S1). This is in contrast to our previous observations in Fgfr3
K644E 
Pten, which 
showed histopathological changes indicative of urothelial neoplasia
 
[30,31].  
 
Next, we used a carcinogen, OH-BBN, to induce invasive bladder cancer. Since bladder cancer 
is known to be more frequent in males than females in humans and in mice [37,38], we analysed 
the effects in both genders individually (the main Figures show the combined results from 
males/females. Results of individual genders are provided in the supplementary Figures, and are 
summarised in supplementary material, Table S1). At 20 weeks from the start of the carcinogen 
treatment, mice did not show any overt sign of adverse effects such as haematuria, although 
tumours in some animals were evident at dissection (Table 1). Metastases were not obvious in 
any of the cohorts. Subsequently, tumour pathogenesis in the bladder was evaluated 
histopathologically (Figure 2). Tumour pathogenesis in FGFR3
S249C
 bladders was more 
advanced in contrast to Wildtype (p=0.0454) (Figure 2I). The invasive nature of the urothelial 
cells and the tumours was also increased in FGFR3
S249C 
(p=0.0239) (Figure 2J). Carcinogen 
treatment caused the urothelium to show distinct characteristics, including a lobulated basement 
membrane (Figure 2E) and squamous transformation and keratinisation (Figure 2F). These 
features were also found to be increased in FGFR3
S249C
 compared to Wildtype (p=0.0073 and 
<0.0001, respectively) (Figure 2K, L). Fgfr3
K644E
 showed two cases of tumour formation (n=2/6 
males) which invaded the stroma (Figure 2I).  
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Overall, the histopathology of carcinogen-induced tumours was more severe in the presence of 
an S249C mutation, indicating that both tumour occurrence and progression were enhanced. The 
phenotype of the Fgfr3
K644E
 cohort was less severe than that of the FGFR3
S249C
 mice, indicating 
that the two FGFR3 mutations are functionally distinct.  
 
Differential time course of urothelial pathogenesis caused by the two FGFR3 mutations 
 
We examined the bladder phenotype along the time course of carcinogen treatment (Figure 3, 
Table 1). Two weeks of OH-BBN treatment typically induced atypia and dysplasia and 
occasional hyperplasia of the urothelium (Figure 3A-C). Contrary to the phenotype at 20 weeks, 
these characteristics were reduced in the FGFR3
K644E
 urothelia (n=10, comparing to Wildtype, 
n=17, p=0.0107) (Figure 3G).  
 
At 12 weeks from the start of OH-BBN treatment, which included 10 weeks of OH-BBN dosing 
in drinking water and 2 weeks that followed without OH-BBN, the urothelium showed clearer 
characteristics of tumour pathogenesis, including carcinoma in situ (CIS) (Figure 3D-F). 
Lobulation of the basement membrane and squamous transformation was also apparent (Fig 3E, 
F). A statistically significant increase in urothelial pathogenesis and lobulation was found in 
Fgfr3
K644E
 (p=0.0128 and 0.0296, respectively) (Figure 3H, I).  
 
Taken together, the increase in tumour pathogenesis became evident as early as 12 weeks from 
the start of the carcinogen treatment. Unexpectedly, at an early phase of carcinogen induction (2 
week-time point), the histopathological changes in the urothelium were suppressed in the 
presence of FGFR3 K644E mutation, indicating differential regulation of urothelial 
pathogenesis by the two FGFR3 mutation.  
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Neutrophil infiltration was suppressed in FGFR3
S249C
 bladders upon carcinogen induction  
 
In an attempt to understand the mechanisms that underlie tumour pathogenesis in FGFR3 
mutant urothelium, we compared the effects of DNA damage caused by OH-BBN, by analysing 
the levels of γH2AX, p53, p21 and Ki67 (Fig S4), as well as indicators for signalling pathways, 
including phosphorylation of ERK, AKT, cJUN and STAT3 (data not shown). No alterations 
were found in DNA damage response and downstream signalling pathways in the FGFR3
S249C
 
urothelium.  
 
An acute inflammatory response caused by the administration of OH-BBN was apparent in the 
Wildtype bladders at 2 weeks (Figure 3K), in contrast to those not treated by OH-BBN (Figure 
3J). The stroma of the OH-BBN-treated bladders was swollen and thickened, accompanied by 
small blood vessels forming at the inner stroma near the urothelium, and larger vessels were 
observed closer to the muscle. The overall inflamed appearance of the stroma, scored as stroma 
thickness and number of blood vessels, was similar between FGFR3 mutant and Wildtype 
cohorts (supplementary material, Figure S5A,B). Recruitment of neutrophils to the urothelium, 
the stroma, and to the muscle layer was clearly observed (Figure 3N), while effectively no 
neutrophils were observed in untreated bladders (Figure 3M). At 12 weeks from the start of OH-
BBN treatment (2 weeks after the last carcinogen treatment), the stroma was typically less 
swollen than at 2 weeks (Figure 3L), however neutrophils remained to be frequently observed 
(Figure 3O).  
 
Interestingly, by scoring the degree of neutrophil infiltration, suppression of neutrophil 
recruitment to the bladder became apparent in FGFR3
S249C
 compared to Wildtype mice at 2 
weeks (p=0.0466, 0.0063, and 0.0464 in the urothelium, stroma, and muscle, respectively) 
(Figure 4A). Infiltration of F4/80
+
 macrophages was also assessed in FGFR3
S249C
, indicating 
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that similar suppression may exist in the FGFR3
S249C
 urothelium (supplementary material, 
Figure S5C). At 12 weeks, neutrophil recruitment was no longer suppressed in FGFR3
S249C
 
(Figure 4B). In contrast to 2 weeks, an increase in neutrophil infiltration was observed in 
Fgfr3
K644E
 stroma compared to Wildtype (p=0.0229) (Figure 4B).  
 
We also investigated the status of tumour inflammation at 20 weeks. Interestingly, tumours were 
mildly more infiltrated by inflammatory cells in FGFR3
S249C
 compared to Wildtype (p=0.018) 
(Figure 4C). One of two Fgfr3
K644E
 tumours was highly infiltrated with neutrophils (score 3), 
while the other was not (score 0). The level of T-cell infiltration was similar in FGFR3
S249C
 and 
Wildtype tumours (supplementary material, Figure S7).  
 
These results indicate that the acute inflammatory response to carcinogen treatment, particularly 
the recruitment of neutrophils to the bladder, was transiently suppressed in the presence of 
FGFR3 S249C mutation at the pre-tumour stage (2 weeks), while at 20 weeks, FGFR3
S249C
 
bladders were mildly more inflamed than Wildtype.  
 
Neutrophil depletion during pre-tumour stage resulted in increased inflammation 
 
The early suppression of an acute inflammatory response could result in chronic inflammation 
later along the process of tumour progression, leading to enhanced tumour pathogenesis in the 
bladder. To investigate this, neutrophils were depleted using a monoclonal antibody against Ly-
6G
+
 (1A8) along with OH-BBN treatment in a cohort of Wildtype mice [39] (Figure 5A). At 2 
weeks of depletion, 1A8-treated mice showed significantly lower circulatory neutrophils in 
comparison with the isotype 2A3-treated control mice (Figure 5B). The neutrophils-to-
lymphocyte ratio (NLR) in the blood was similarly reduced upon 1A8-treatment (Figure 5C). At 
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the tissue level, neutrophils were indicated to be effectively suppressed in the urothelium of 
1A8-treated mice in comparison to 2A3-treated mice (supplementary material, Figure S8A).  
 
Next, we sought to determine how neutrophil depletion during the pre-tumour stage would 
affect tumour progression. 1A8 was synchronously administered with OH-BBN for 10 weeks, 
and the levels of neutrophils were examined at 20 weeks. In contrast to the 2 weeks' time point, 
mice had a significantly higher NLR when previously treated with 1A8 (p=0.0317) (Figure 5E). 
Levels of neutrophil infiltration in the tumour tissue were comparable (Fig S8B). Interestingly, 
depletion of neutrophils during the pre-tumour stage indicated mildly more enhanced severity of 
tumour pathogenesis at 20 weeks (Figure 5F).  
 
The results of the neutrophil depletion study indicated that the impairment of the acute 
inflammatory response at the pre-tumour stage could lead to a later increase in the levels of 
circulatory immune cells, indicative of enhanced progression of bladder tumours. This supports 
our hypothesis that the transient suppression of neutrophil recruitment to the bladder in FGFR3 
S249C mice at the pre-tumour stage could account for increased tumorigenesis.  
 
Early inflammatory phenotypes are associated with FGFR3 mutations, while late-phase 
inflammation is associated with tumour progression.  
 
Changes in the levels of inflammatory infiltrations could be genotype-dependent (ie, changes in 
signalling by FGFR3 mutant proteins may have regulated the level of inflammation), or 
alternatively, phenotype-dependent (ie, inflammatory phenotype may have been caused by the 
severity of bladder/tumour pathology). In order to address this, we analysed the correlation 
between genotypes (cohort), phenotypes, and inflammation (supplementary material, Table S2-
S4).  
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At 2 weeks, dysplasia significantly correlated with the cohort (Spearman’s rank test rho: -0.405; 
p=0.007) (supplementary material, Table S2.1). The Kruskal-Wallis test showed that differences 
seen among cohorts were statistically significant in dysplasia (p=0.025), neutrophils in the 
stroma (p=0.003), and in the muscle (p=0.017) (supplementary material, Table S2.4), indicating 
that both dysplasia and inflammation were genotype-dependent.  
 
At 12 weeks, cohort-dependent differences were evident in lobulation (rho: 0.435; p=0.021) and 
neutrophils in the stroma (rho: 0.435; p=0.022) (supplementary material, Table S3.1). 
Neutrophils in the stroma was also correlated with bladder phenotypes, including lobulation 
(rho: 0.671; p=0.00009), and squamous transformation (rho: 0.508; p=0.006). However, no 
statistically significant links were observed regarding neutrophils by the Kruskal-Wallis tests, 
either controlled by genotype (supplementary material, Table S3.4), or by pathogenesis 
(supplementary material, Table S3.7). 
 
At 20 weeks, a positive correlation was evident in scores that indicate tumour pathogenesis 
(pathogenesis, invasiveness, lobulation and squamous transformation) and inflammation (overall 
inflammation in the urothelium, stroma, muscle and tumours) (supplementary material, Table 
S4.1). A significant correlation with cohort was seen in squamous transformation (rho: 0.323; 
p=0.002) (supplementary material, Table S4.1). Inflammation scores were notably correlated 
with those of pathogenesis. The Kruskal-Wallis test showed that inflammation in tumours was 
associated with pathogenesis (supplementary material, Table S4.7) and invasiveness 
(supplementary material, Table S4.10), however, no association was evident when controlled by 
cohort (supplementary material, Table S4.4). 
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Taken together, at an early phase of carcinogen induction, regulation of pathogenesis and 
inflammatory response was associated with the FGFR3 genotype, indicating the direct causative 
effects of the FGFR3 mutations. Once carcinogen treatment had ceased (12 weeks), 
inflammation was no longer regulated by FGFR3 mutations. At 20 weeks, only tumour 
pathogenesis was associated with FGFR3 genotype, and inflammation was associated with 
tumour progression.   
 
In humans, tumours with FGFR3 mutation are associated with the urothelial-like or luminal 
papillary tumour subgroup that is generally characterised by lower levels of lymphocytic 
infiltration [7,13,40,41]. Here we stratified TCGA data [7] by FGFR3 mutation status and 
compared the immune gene expression signature [42]. In human MIBC, FGFR3 mutation did 
not influence the level of immune signature in any of the urothelial-like/luminal subtypes 
(supplementary material, Figure S9A,B). When subtypes were grouped together, human 
urothelial-like/luminal tumours with FGFR3 mutation were less immune-infiltrated than those 
with wild-type status (supplementary material, Figure S9C,D). However, this is due to the 
prevalence of Urothelial-like A-progressed (UroA-prog)/luminal-papillary subtypes that harbour 
FGFR3 mutations more frequently, and these subtypes were less immune infiltrated among the 
group regardless of FGFR3 mutation status (supplementary material, Figure S9A,B).   
 
Discussion 
 
By studying the effects of FGFR3 mutations using OH-BBN induced, genetically engineered 
mouse models of invasive bladder cancer, we report three significant findings:  Firstly, in the 
presence of mutationally activated FGFR3 S249C, there was an increased number of mice that 
developed bladder tumours, and the tumour phenotype was more advanced (Figure 2). In 
FGFR3
S249C
, tumour cells were more undifferentiated and invasive, with an increase in 
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squamous metaplasia. In the context of the skin, FGFR3 is expressed in keratinocytes, and 
FGFR3 mutation was associated with seborrheic keratosis [43]. Keratinisation in the mouse 
model in this study can be interpreted as an advanced feature of tumour progression.  Secondly, 
the inflammatory response was unexpectedly suppressed in the presence of an S249C mutation 
at an early time of carcinogen induction (Figure 4). Acute inflammation is associated with an 
anti-tumour response [8]. A reduced clearance of DNA-damaged cells may have led to overall 
increased tumour formation in FGFR3
S249C
 at later stages (proposed in Figure 6). Although 
involvement of FGF signalling has been reported in inflammatory diseases and in the tumour 
microenvironment [44], the mechanisms that underlie early suppression of inflammatory 
response by S249C-mutated FGFR3 are currently unknown. FGFR3 is not expressed in 
neutrophils [45]. FGFR3 mutations are not associated with smoking [46], and are not found in 
OH-BBN-induced tumours in mice [47]. Studies on genomic and transcriptional profiles of the 
tumour samples generated in this study may be useful in order to gain further mechanistic 
insights into the suppression of acute inflammation and tumorigenesis in the presence of FGFR3 
mutations.  Thirdly, established tumours in FGFR3
S249C
 were mildly more inflamed compared to 
Wildtype tumours (Figure 4). This increase in inflammation was mainly associated with overall 
tumour progression, rather than FGFR3 mutations (supplementary material, Table S4). No 
significant differences were observed in the levels of T-cells (supplementary material, Figure 
S7). Neutrophil depletion at an early phase increased the NLR later at 20 weeks, during the 
timeframe of tumour establishment and progression, indicative of enhanced tumour 
pathogenesis (Figure 5). A high circulatory NLR is generally associated with poor prognosis, 
including in bladder cancer [48-51]. However, the level of neutrophils in the tumours remained 
similar regardless of early depletion (supplementary material, Figure S8). Therefore, effects of 
immune microenvironment on tumour progression are not expected in this model (Figure 5F). 
Whether suppression of acute inflammatory response leads to tumour inflammation, and 
whether such inflammation reciprocally enhances tumour progression, remain unresolved.  
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FGFR3 mutations are commonly found in urothelial-like/luminal papillary tumour subtypes 
generally associated with better prognosis, and accompanied by low levels of lymphocytic 
infiltration [7,13,40,41]. In the context of PD-1/PD-L1 checkpoint blockade therapy, presence of 
T-cell populations was shown to be an important indicator for the patients’ response, where low 
levels of CD3
+
 and CD8
+
 T-cells are associated with poor outcome [9,51,52]. It has been 
reported recently that FGFR3 mutations are frequently found in non-CD8
+
 T-cell-inflamed 
MIBC, and it was proposed that FGFR3 pathway could be targeted to overcome resistance and 
sensitise tumours to PD-1/PD-L1 immunotherapy [40]. Our analysis of urothelial-like/luminary 
papillary tumour subtypes in the TCGA dataset showed that the expression of immune genes 
was not affected by the presence or absence of FGFR3 mutations in each of the different 
subtypes of the Lund or TCGA classification (supplementary material, Figure S9). This included 
the Urothelial-like B (UroB), a subtype with the worst overall survival, similar to Small-
cell/Neuroendocrine-like (Sc/NE-like) [13]. Lower infiltration was indeed associated with 
FGFR3 mutation when all subtypes within urothelial-like/luminary papillary subtypes were 
combined, however, this is due to frequency of lower-infiltrated subgroups, such as UroA-
Prog/Luminal-papillary subtypes (supplementary material, Figure S9C,D). The lack of 
difference in immune gene expression within the tumour subtype in the presence and absence of 
FGFR3 mutation in human MIBC could be due to the fact that human studies are based on 
established tumours, while our study in mouse models investigates the functional effects of 
FGFR3 along the process of tumour initiation and development, the earlier phases in tumour 
pathogenesis. It would be interesting to compare the levels of tumour inflammation in OH-
BBN-induced bladder models with other molecular changes, such as Tp53, Stat3 and Sparc 
models [53]. To facilitate the evaluation, we have previously generated the "Tumour 
Progression Scale" in phenotyping mouse bladder tumours with an inflammatory phenotype 
[54].   
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Examining the individual FGFR3 mutations, early suppression of neutrophil infiltration was not 
present in the Fgfr3
K644E
 (Figure 4). Instead, an increase in pathogenesis was observed at 2 
weeks and 12 weeks (Figure 3) and stromal neutrophil infiltration was increased in Fgfr3
K644E
 
(Figure 4B), indicating earlier kinetics in urothelial pathogenesis. Nonetheless, it did not lead to 
a significant increase in tumorigenesis at the 20-week endpoint (Figure 2). Therefore, the effects 
of individual FGFR3 mutations in regulating neutrophils and tumour pathogenesis are distinct, 
and may explain the low frequency of kinase domain mutations in human bladder neoplasia. 
Mechanistically, the way these two mutations regulate the receptor protein kinase function and 
downstream signalling could be different [15,16]. For example, S249C leads to phosphorylation 
of PLCwhile the equivalent kinase domain mutation K652E does not [55]. The cell-cell and 
cell-matrix adhesion were also indicated to be differently regulated in cells expressing S249C 
and K652E [56]. Effects of gender in bladder cancer epidemiology and underlying mechanism 
are well discussed [37,38]. The results of male/female combined analyses were consistent with 
those done individually (summarised in supplementary material, Table S1). However, a small 
number of mice used may have masked any effects.    
 
In summary, our study showed that the increased tumour progression could be initiated by the 
effects of FGFR3 mutations in regulating an acute inflammatory response, and that immune 
cells are perturbed in the tumour as a consequence. Clinically, it would be beneficial to explore 
FGFR3 inhibition together with the concurrent immune modulators, such as BCG, as a potential 
treatment strategy for FGFR3-mutated or -overexpressing bladder cancer at an early stage.  
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Table 1. Summary of the mouse
 
cohorts 
Models of spontaneous tumour formation 
Genotype Age 
at time of 
analysis 
Cohort size (n) 
Male (m) 
Female (f) 
Gross observation at 
time point 
Control 
 
10-18 months 
 
11 (m = 1; f =10) 
 
None 
FGFR3
S249C
 6-12 months 17 (m =10; f = 7) Non-bladder related 
death in n=2 (12%) 
 
FGFR3
S249C
Pten 12 months 12 (m = 6; f = 6) Non-bladder related 
death in n=1 (8%) 
Carcinogen-induced bladder cancer model 
Genotype OH-BBN 
treatment 
(weeks) 
Cohort size (n) 
Male (m) 
Female (f) 
Gross observation at 
time point 
Wild type 2 17 (m=8; f=9) None 
 12 10 (m=3; f=7) None 
 20 47 (m=20; f=27) Tumour (m=5; f=1) 
 
FGFR3
S249C
 2 15 (m=10; f=5) None 
 12 10 (m=3; f=7) None 
 20 29 (m=12; f=17) Tumour (m=3; f=6) 
 
FGFR3
K644E
 2 11 (m=4; f=7) None 
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 12 8 (m=3; f=5) None 
 20 11 (m=6; f=5) Tumour (m=2; f=0) 
The Tg(UroII-hFGFR3IIIbS249C) mouse line (FGFR3
S249C
) was generated as described in 
Supplementary Methods. UroIICre [57], Pten
flox/flox
 [58] were intercrossed with FGFR3
S249C
 to 
generate FGFR3
S249C
 Pten
flox/flox
 mice (FGFR3
S249C 
Pten). The Controls were C57Bl/6 (Charles 
River, UK) ("Wildtype") (n=7) and mice with transgenic alleles which do not lead to any 
phenotype (n=4). Genetic background was C57Bl/6 in all cohorts. For carcinogen induction, 
mice at 8-16 weeks of age were administered with 0.05% (v/v) OH-BBN in drinking water for 
10 weeks followed by 10 weeks of normal drinking water. Mice used were Wildtype, 
FGFR3
S249C
 and UroIICre Fgfr3
+/K644E
 (FGFR3
K644E
) [31]. 
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Figure legends 
 
Figure 1. Schematic presentation of the mouse cohorts studied and timeline of carcinogen 
induction. The role of FGFR3 mutations was investigated using models of spontaneous tumour 
formation (left). FGFR3 mutation by itself, either K644E [30,31] or S249C (this study), did not 
lead to urothelial pathogenesis. While double mutant mice Fgfr3
K644E 
Pten resulted in 
histopathological abnormalities
 
[31], FGFR3
S249C 
Pten bladders did not show any noticeable 
histological changes at 12 months. For carcinogen-induced model of invasive bladder tumours 
(right), tobacco carcinogen, OH-BBN. 0.05% (v/v) OH-BBN was administered to mice in 
drinking water for the first 10 weeks, then tumours were allowed to develop for a further 10 
weeks. The histopathology of the bladders and tumours was examined at 2, 12 and 20 week time 
points.  
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Figure 2. Histopathology of the urothelium and bladder tumours at 20 weeks from the 
start of carcinogen treatment.  
Representative images of minimal changes (A), hyperplasia (B), dysplasia (C), carcinoma in situ 
(CIS) (D). The basement membrane was often lobulated (E) and the urothelium was squamous 
transformed with keratinised surfaces (arrowhead) (F). An additional examples of CIS (red 
arrowhead) is indicated in examples of fully developed tumours (G, H) with stromal invasion 
(black arrowhead) (G). The leading edge of the invading tumour was often infiltrated with 
inflammatory cells (arrowhead in H). Scale bar represents 50 µm in A,B,E, 70 µm in C, 100 µm 
in D, 125 µm in F, 500 µm in G and 700 µm in H. (I-L) The observed phenotype was shown as 
percentage of mice that showed the specific phenotypic criterion. (I) Pathogenesis observed in 
the bladder. (J) Invasiveness of the urothelial and tumour cells. (K) Lobulated appearance of the 
basement membrane. (L) Squamous differentiation observed in the urothelium and the tumour. 
In I-L, Number of samples analysed was n=47, 29, and 11, for Wildtype, FGFR3
S249C
 and 
Fgfr3
K644E
, respectively (results for males and females combined are shown here). The p-values 
(Mann-Whitney) are indicated above the columns, when significant (*<0.05 and **< 0.005). 
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Figure 3. Histopathological and inflammatory phenotype of the bladder at 2 and 12 weeks 
from the start of carcinogen treatment.   
Representative H&E images of the urothelium of Wildtype (A, D), FGFR3
S249C 
(B, E) and 
Fgfr3
K644E
 (C, F) at 2 (A-C) and 12 weeks (D-F) from the start of OH-BBN treatment. 
Lobulated basement membrane (arrowheads in E) and squamous transformation (arrowheads in 
F) was visible at 12 weeks. (G) Presence of atypia and dysplasia in the urothelium at 2 weeks 
was scored in n=17, 15, and 10 samples of Wildtype, FGFR3
S249C
 and Fgfr3
K644E
, respectively. 
Pathogenesis (H) and lobulation of the basement membrane (I) at 12 weeks were scored in 
n=10, 10, and 8 samples of Wildtype, FGFR3
S249C
 and Fgfr3
K644E, 
respectively. The Y-axis 
indicates percentage of mice that showed the specific phenotypic criterion. The p-values (Mann-
Whitney) are indicated when significant (*<0.05). In the absence of OH-BBN, no sign of 
inflammation was present, and no neutrophils were observed (J, M). In contrast, 2 weeks of 
carcinogen treatment caused the bladder to be inflamed with thickened stroma with inner and 
outer bands (K), with increased presence of neutrophils in the urothelium and in the stroma 
(arrowheads in N). At 12 weeks from the start of the carcinogen treatment (2 weeks after mice 
had been returned to the normal drinking water), the bladders showed a mixture of inflamed and 
normal areas (L). Neutrophils were also observed at 12 weeks (arrowheads) (O). Scale bar 
represents 100 µm in A-F, 300 µm in J, K, 500 µm in L, 50 µm in M-O.  
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Figure 4. Infiltration of neutrophils in the bladder and bladder tumours at time points of 
carcinogen treatment.  
Presence of neutrophils in the urothelium, stroma, and muscle layer of the bladder at 2 weeks 
(A) and 12 weeks (B) from the start of OH-BBN treatment. (C) The status of overall 
inflammation (left) and infiltration of neutrophils (right) in the tumours observed at 20 weeks 
from the start of OH-BBN treatment. The Y-axis indicates percentage of mice that showed the 
specific phenotypic criterion. Number of samples analysed is indicated below each column. The 
p-values (Mann-Whitney) are indicated where significant (*<0.05 and **< 0.005). 
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Figure 5. Depletion of Ly-6G
+
 neutrophils to suppress OH-BBN induced inflammation in 
the bladder 
 
(A) Schematic presentation of the experiment. A monoclonal antibody against Ly-6G (1A8), 
was administered to mice during OH-BBN treatment for 10 weeks. Clone 2A3 was used as an 
isotype control. The composition of the white blood cells was analysed at 2 weeks (B, C), and at 
20 weeks (D, E) from the start of OH-BBN treatment. Each leukocyte subtype was presented as 
a proportion within the total white blood cell population (% WBC). (C, E) Neutrophil-to-
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lymphocyte ratio (NLR). (F) Pathogenesis in the bladder at the endpoint, shown as percentage 
of mice with the specific phenotypic criterion. Number of samples analysed is indicated below 
each column. The p-values (Mann-Whitney) are indicated where significant (*<0.05 and **< 
0.005). 
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Figure 6: Proposed model of the mechanism underlying increased tumour development in 
the presence of an FGFR3 S249C mutation. Carcinogen induces DNA damage in the 
urothelium as well as an inflammatory response in the bladder that recruits neutrophils to the 
sites of damage. The balance between DNA damage and clearance of cells that harbour 
oncogenic mutations by inflammatory response determines the occurrence of the tumour and its 
pathogenesis. In FGFR3
S249C
, reduced inflammatory response at early stages may impair the 
clearance of DNA-damaged cells, leading to increased tumour formation and severity at later 
stage. Enhanced tumour pathology may accompany perturbation of tumour inflammation. Early-
phase depletion of neutrophils during tumour initiation led to increased circulatory inflammation 
at a later stage, indicative of enhanced tumour pathogenesis, which supports that suppression of 
acute inflammation could play a causative role in tumour pathogenesis.     
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